타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials | |||
|---|---|---|---|---|---|
Overview Program | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin-ejfv) | Adstiladrin (nadofaragene firadenovec) | Disitamab Vedotin (RC48) | Tremelimumab |
Overview Company | Roche / Genentech | Astellas / Pfizer (Seagen) | Ferring Pharmaceuticals | RemeGen | AstraZeneca |
Overview Modality | ANTIBODY | ADC | CGT | ADC | ANTIBODY |
Overview Target | PD-L1 | Nectin-4 | IFNα2b (adenoviral) | HER2 | Muscle Invasive Bladder Cancer |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) | HER2+ urothelial, gastric, breast | Hepatocellular Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Local bladder gene delivery avoiding systemic AAV exposure | Novel anti-HER2 mAb with distinct epitope | novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database |
Positioning Known limitation | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | resistance to apoptosis, and metastasis |
Positioning Development positioning | — | 1L with pembrolizumab; monotherapy in later lines | — | 2L+ | — |
Technology Payload | — | MMAE (monomethyl auristatin E, tubulin inhibitor) | — | MMAE | — |
Technology Linker | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 | — | Cleavable | — |
Technology DAR | — | DAR 3.8 | — | — | — |
Technology Vector | — | — | rAd-IFNα/Syn3 | — | — |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey | Cynomolgus monkey | — |
Toxicology Animal (cat.) | — | — | — | NHP | — |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — |
Toxicology CRS | N/A | N/A | N/A | N/A | — |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — |
Clinical Selected reported efficacy | — | 95% | — | — | — |
Clinical Reported PFS | — | 12.5 months vs 6.3 months (platinum chemotherapy) | — | — | — |
Clinical Reported OS | — | 31.5 months vs 16.1 months (platinum chemotherapy) | — | — | — |
Clinical Result source | — | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | 6 recruiting · 3 completed | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04223856 | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials | |||
|---|---|---|---|---|---|
Overview Program | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin-ejfv) | Adstiladrin (nadofaragene firadenovec) | Disitamab Vedotin (RC48) | Tremelimumab |
Overview Company | Roche / Genentech | Astellas / Pfizer (Seagen) | Ferring Pharmaceuticals | RemeGen | AstraZeneca |
Overview Modality | ANTIBODY | ADC | CGT | ADC | ANTIBODY |
Overview Target | PD-L1 | Nectin-4 | IFNα2b (adenoviral) | HER2 | Muscle Invasive Bladder Cancer |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) | HER2+ urothelial, gastric, breast | Hepatocellular Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Local bladder gene delivery avoiding systemic AAV exposure | Novel anti-HER2 mAb with distinct epitope | novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database |
Positioning Known limitation | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | resistance to apoptosis, and metastasis |
Positioning Development positioning | — | 1L with pembrolizumab; monotherapy in later lines | — | 2L+ | — |
Technology Payload | — | MMAE (monomethyl auristatin E, tubulin inhibitor) | — | MMAE | — |
Technology Linker | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 | — | Cleavable | — |
Technology DAR | — | DAR 3.8 | — | — | — |
Technology Vector | — | — | rAd-IFNα/Syn3 | — | — |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
Toxicology Species | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey | Cynomolgus monkey | — |
Toxicology Animal (cat.) | — | — | — | NHP | — |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — |
Toxicology CRS | N/A | N/A | N/A | N/A | — |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — |
Clinical Selected reported efficacy | — | 95% | — | — | — |
Clinical Reported PFS | — | 12.5 months vs 6.3 months (platinum chemotherapy) | — | — | — |
Clinical Reported OS | — | 31.5 months vs 16.1 months (platinum chemotherapy) | — | — | — |
Clinical Result source | — | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | 6 recruiting · 3 completed | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04223856 | — | — | — |
추천 비교
추천 비교